Trial reportClinical cancer research : an official journal of the American Association for Cancer Research2009
KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803.
Trial report in Clinical cancer research : an official journal of the American Association for Cancer Research, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 109 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
109 citing papers in PubMed, 1 synthesis or guideline pooled it, 196 citations in OpenAlex.
- Pooled it
- Evaluating the utility ofEpigenetics · 2024Trial
- Trial
- Famitinib versus placebo in the treatment of refractory metastatic colorectal cancer: a multicenter, randomized, double-blinded, placebo-controlled, phase II clinical trial.Chinese journal of cancer · 2017Trial
- Trial
- Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes.Gastroenterology · 2015Trial
- CpG island methylator phenotype is associated with response to adjuvant irinotecan-based therapy for stage III colon cancer.Gastroenterology · 2014Trial
- KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild-type stage III colon cancers from an adjuvant chemotherapy trial (N0147 alliance).Clinical cancer research : an official journal of the American Association for Cancer Research · 2014Trial
- Predictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial.Journal of the National Cancer Institute · 2013Trial
- Prognostic impact of deficient DNA mismatch repair in patients with stage III colon cancer from a randomized trial of FOLFOX-based adjuvant chemotherapy.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2013Trial
- An analysis of the treatment effect of panitumumab on overall survival from a phase 3, randomized, controlled, multicenter trial (20020408) in patients with chemotherapy refractory metastatic colorectal cancer.Targeted oncology · 2013Trial
- Phase III randomized, placebo-controlled trial of docetaxel with or without gefitinib in recurrent or metastatic head and neck cancer: an eastern cooperative oncology group trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2013Trial
- Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803.Clinical cancer research : an official journal of the American Association for Cancer Research · 2012Trial
- Relationship between statin use and colon cancer recurrence and survival: results from CALGB 89803.Journal of the National Cancer Institute · 2011Trial
- Cetuximab for the treatment of advanced bronchioloalveolar carcinoma (BAC): an Eastern Cooperative Oncology Group phase II study (ECOG 1504).Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2011Trial
- KRAS and BRAF mutations modify adjuvant chemotherapy outcomes in early stage colorectal cancer.NPJ precision oncology · 2026Article
- KRAS Mutation Status as a Prognostic Marker and Predictor of Therapy Response in Colorectal Cancer: an NCDB Analysis.Journal of gastrointestinal cancer · 2026Article
- A cautionary tale: an evaluation of the performance of treatment switching adjustment methods in a real world case study.BMC medical research methodology · 2024Article
- Reclassification ofTherapeutic advances in medical oncology · 2024Article
- KRAS Sequence Variation as Prognostic Marker in Patients With Young- vs Late-Onset Colorectal Cancer.JAMA network open · 2023Article
49 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 8 institutions in 1 country.
Funding
Abstract
purposeAlterations in the RAS and RAF pathway relate to epigenetic and epigenomic aberrations, and are important in colorectal carcinogenesis. KRAS mutation in metastatic colorectal cancer predicts resistance to anti-epidermal growth factor receptor (EGFR)-targeted therapy (cetuximab or panitumumab). It remains uncertain, however, whether KRAS mutation predicts prognosis or clinical outcome of colon cancer patients independent of anti-EGFR therapy.
methodsWe conducted a study of 508 cases identified among 1,264 patients with stage III colon cancer who enrolled in a randomized adjuvant chemotherapy trial (5-fluorouracil, leucovorin with or without irinotecan) in 1999-2001 (CALGB 89803). KRAS mutations were detected in 178 tumors (35%) by pyrosequencing. Kaplan-Meier and Cox proportional hazard models assessed the prognostic significance of KRAS mutation and adjusted for potential confounders including age, sex, tumor location, tumor/node stage, performance status, adjuvant chemotherapy arm, and microsatellite instability status.
resultsCompared with patients with KRAS-wild-type tumors, patients with KRAS-mutated tumors did not experience any difference in disease-free, recurrence-free, or overall survival. The 5-year disease-free, recurrence-free, and overall survival rates (KRAS-mutated versus KRAS-wild-type patients) were 62% versus 63% (log-rank P = 0.89), 64% versus 66% (P = 0.84), and 75% versus 73% (P = 0.56), respectively. The effect of KRAS mutation on patient survival did not significantly differ according to clinical features, chemotherapy arm, or microsatellite instability status, and the effect of adjuvant chemotherapy assignment on outcome did not differ according to KRAS status.
conclusionsIn this large trial of chemotherapy in stage III colon cancer patients, KRAS mutational status was not associated with any significant influence on disease-free or overall survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.